“Clozapine & Valbenazine for Treatment of Tardive Cervical Dystonia: A Case Report”

Tardive Cervical Dystonia





Dystonia, antipsychotics, schizophrenia


Cervical dystonia is a subtype of tardive dyskinesia characterized by smooth, sustained muscle contractions affecting the head, neck, and shoulders. This condition can be caused by antipsychotic medication exposure. It has a significant impact on the patient’s quality of life and represents a treatment challenge for providers. We present the case of a 26-year-old male with a history of schizophrenia treated with antipsychotic medications who presented with on and off smooth twisting movements of his neck and hand tremors. He was initially treated with benztropine and a decrease in the dose of his antipsychotic medications. However, when his symptoms continued to worsen, he was cross tapered to clozapine and valbenazine. Valbenazine is a VMAT2 inhibitor FDA approved for treatment of tardive dyskinesia, but there is little data regarding its use for tardive dystonia. The cervical dystonia impact profile-58 (CDIP-58) was administered to monitor the patient’s symptoms. Overall, there was a reduction in cervical dystonia symptoms within a 10-week period. This case illustrates the potential for clozapine plus valbenazine to treat tardive cervical dystonia.



Casey D (1990) Tardive dyskinesia. Western journal of medicine 153(5):535.

Burke RE; Fahn S; Jankovic J; Marsden C; Lang AE; Gollomp S, et al. (1982) Tardive dystonia: late?onset and persistent dystonia caused by antipsychotic drugs. Neurology 32(12):1335. DOI: https://doi.org/10.1212/WNL.32.12.1335

Molho ES; Feustel PJ; Factor SA (1998) Clinical comparison of tardive and idiopathic cervical dystonia. Movement disorders 13(3):486-9. DOI: https://doi.org/10.1002/mds.870130319

Godeiro-Junior C; Felício AC; de Carvalho Aguiar P; Borges V; Silva SM; Ferraz HB (2009) Neuroleptic-induced tardive cervical dystonia: clinical series of 20 patients. Canadian journal of neurological sciences 36(2):222-6. DOI: https://doi.org/10.1017/S0317167100006582

Skidmore F; Reich SG (2005) Tardive dystonia. Current treatment options in neurology 7(3):231-6. DOI: https://doi.org/10.1007/s11940-005-0016-0

van Harten PN; Kahn RS (1999)Tardive dystonia. Schizophrenia bulletin 25(4):741-8. DOI: https://doi.org/10.1093/oxfordjournals.schbul.a033415

Wojcik JD; Falk WE; Fink JS; Cole JO; Gelenberg AJ (1991) A review of 32 cases of tardive dystonia. The American journal of psychiatry 148(8), 1055–1059. DOI: https://doi.org/10.1176/ajp.148.8.1055

Yassa R; Nair V (1986) Dimitry R. Prevalence of tardive dystonia. Acta psychiatrica scandinavica 73(6):629-33. DOI: https://doi.org/10.1111/j.1600-0447.1986.tb02735.x

Duggal HS; Mendhekar DN (2008) Risperidone-induced tardive pharyngeal dystonia presenting with persistent dysphagia: a case report. Primary care companion to the Journal of clinical psychiatry 10(2):161. DOI: https://doi.org/10.4088/PCC.v10n0213b

Thenganatt MA; Jankovic J (2014) Treatment of dystonia. Neurotherapeutics 11(1):139-52. DOI: https://doi.org/10.1007/s13311-013-0231-4

Jinnah HA; Comella CL; Perlmutter J; Lungu C; Hallett M; Investigators DC (2018) Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Toxicon 147:89-95. DOI: https://doi.org/10.1016/j.toxicon.2017.09.004

Tarakad A. (2020) Clinical Rating Scales and Quantitative Assessments of Movement Disorders. Neurologic Clinics 38(2):231-54. DOI: https://doi.org/10.1016/j.ncl.2019.12.001

Loonen AJ; Ivanova SA (2020) Neurobiological mechanisms associated with antipsychotic drug-induced dystonia. Journal of Psychopharmacology 0269881120944156. DOI: https://doi.org/10.1177/0269881120944156

Greene P. Treatment of Tardive Dystonia. Therapy of Movement Disorders: Humana, Cham, 2019: 287-9. DOI: https://doi.org/10.1007/978-3-319-97897-0_65

Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K (2013) Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics: A Meta-Analysis. Journal of Clinical Psychopharmacology 33(5):675-81. DOI: https://doi.org/10.1097/JCP.0b013e3182983ffa

Touma KTB; Scarff JR (2018) Valbenazine and Deutetrabenazine for Tardive Dyskinesia. Innovations in clinical neuroscience 15(5-6):13-6.

Kilbourn MR; Koeppe RA (2019) Classics in Neuroimaging: Radioligands for the Vesicular Monoamine Transporter 2. ACS Chemical Neuroscience 10(1):25-9. DOI: https://doi.org/10.1021/acschemneuro.8b00429

Uhlyar S; Rey JA (2018) Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia. Pharmacy and Therapeutics 43(6):328.




How to Cite

Lewis, C., & Brennan, C. (2023). “Clozapine & Valbenazine for Treatment of Tardive Cervical Dystonia: A Case Report”: Tardive Cervical Dystonia. Translation: The University of Toledo Journal of Medical Sciences, 11(2). https://doi.org/10.46570/utjms.vol11-2023-526